AbCellera Biologics Inc. (NASDAQ: ABCL) announced it will disclose interim results from the Phase 1 portion of its ABCL635 study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE